

ficiary Informatio

1. Beneficiary List Name:			
Prescriber Information 6. Prescriber Name:	1. Beneficiary Last Name: 2. First Name:		
Prescriber Information NPI #: ZIP: Mailing address: City: State: ZIP: Mailing address: Phone #: Fax #: ZIP: Name: Phone #: Fax #: ZIP: Drug Information 9. Strength: 10. Quantity Per 30 Days:	3. Beneficiary ID #: 4. Beneficiary Date of Birth: 5. Beneficiary Gender:		
6. Prescriber Name: NPI #: ZIP: Mailing address: City: State: ZIP: Name: Phone #: Fax #: ZIP: Name: Poil information 9. Strength: 10. Quantity Per 30 Days: 11. Length of Therapy:	Prescriber Information		
7. Regisser Contact Information:	6. Prescriber Name: NPI #:		
Name: Phone #: Fax #: Drug Information 9. Strength: 10. Quantity Per 30 Days:			
Drug Information 8. Drug Name: 0. Strength: 10. Quantity Per 30 Days: 11. Length of Therapy: up to 30 days 60 days 120 days180 days365 days Clinical Information Initial authorization FOR ALL DIAGNOSES: 1. Is the beneficiary 18 years old or older? Yes No 2. Is the beneficiary 18 years old or older? Yes No 2. Is the beneficiary 18 years old or older? Yes No 1. She beneficiary 18 years old or older? Yes No 2. Is the beneficiary 18 years old or older? Yes No 1. She beneficiary 18 years old or older? Yes No 2. Dose the Deneficiary 18 years old or oncer migraine days per month for at least 3 months? Yes No 3. Has the beneficiary reperienced 4 or more migraine days per month for at least 3 months? Yes No 2. Dose the Deneficiary reperienced 4 or more migraine days per month for at least 3 months? Yes No 3. Has the beneficiary reperienced 4 or more migraine days per direct full of medications for networking and the start are women of childbearing age, is there a negative pregnancy test at baseline? Yes No	7. Requester Contact Information:		
Drug Information 8. Drug Name: 9. Strength: 10. Quantity Per 30 Days: 11. Length of Therapy: up to 30 days 60 days 90 days 180 days 365 days Clinical Information	Name: Phone #: Fax #:		
Clinical Information Initial authorization FOR ALL DIAGNOSES: I. Is the beneficiary 18 years old or older? YesNo Is the beneficiary utilizing prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications for preventative treatment of migraines, or medication therapy for episodic cluster headaches)? YesNo Initial authorization for REVENTATUE treatment of Migraines - INJECTABLES and ORALS: Does the beneficiary have a diagnosis of migraine with or without aura based on the International Classification of Headache Disorders criteria? YesNo Does the beneficiary pave adiagnosis of migraine with or without aura based on the International Classification of Headache Disorders criteria? YesNo 3. Has the beneficiary pave medication overuse headache (MOH)? YesNo 1. For beneficiary experienced 4 or more migraine days per month for at teast 3 months? YesNo I. For beneficiary tried and failed at least a month or greater trial of medications from at teast 2 different classes from the following list of oral medications: 1. Antidepressants (e.g., waltriptyline, venlafaxine). 2. Beta Blockers (e.g. propranolol, metoprolol, timolol, atenolol), 3. Anti- epileptics (e.g., valproate, topiramate) 4. Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (e.g., lisinopril, candesartan) 5. Calcium Channel Blockers (e.g., verapamil, nimodipine)Yes No 21. Bus the beneficiary tried and failed at least 2 preferred injectable CGRPS? Yes No 22. Does the Beneficiary tried and failed at least 2 preferred injectable CGRPS? Yes No 23. Noll the Beneficiary tried and failed at least 2 preferred injectable CGRPS? Yes No 24. Does the Beneficiary tried and failed at least 2 preferred indust (Emgality 100mg/ml): 1. Does the Beneficiary tried and failed at least 2 preferred indust (Emgality 100mg/ml): 1. Does the Beneficiary tried and failed at least 2 preferred indust (Emgality 100mg/ml): 1. Does the Benefic			
Clinical Information Initial authorization FOR ALL DIAGNOSES: I. Is the beneficiary 18 years old or older? YesNo Is the beneficiary utilizing prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications for preventative treatment of migraines, or medication therapy for episodic cluster headaches)? YesNo Initial authorization for REVENTATUE treatment of Migraines - INJECTABLES and ORALS: Does the beneficiary have a diagnosis of migraine with or without aura based on the International Classification of Headache Disorders criteria? YesNo Does the beneficiary pave adiagnosis of migraine with or without aura based on the International Classification of Headache Disorders criteria? YesNo 3. Has the beneficiary pave medication overuse headache (MOH)? YesNo 1. For beneficiary experienced 4 or more migraine days per month for at teast 3 months? YesNo 1. For beneficiary tried and failed at least a month or greater trial of medications from at teast 2 different classes from the following list of oral medications: 1. Antidepressants (e.g., waltriptyline, venlafaxine). 2. Beta Blockers (e.g. propranolol, metoprolol, timolol, atenolol), 3. Anti- epileptics (e.g., valproate, topiramate) 4. Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (e.g., lisinopril, candesartan) 5. Calcium Channel Blockers (e.g., verapamil, nimodipine)Yes No 2. Boas the beneficiary tried and failed at least 2 preferred injectable CGRPS? Yes No 2. Convertee ONLY 2. Noll the Beneficiary tried and failed at least 2 preferred injectable CGRPS? Yes No 2. Does the Beneficiary tave end stage renal disease with a creatinine clearance (CrCI) less than 15ml/min? Yes No 2. Does the Beneficiary tave ad diagnosis of Episodic Cluster Headacher Yes No 2. Hos the beneficiary tried and failed at least 2 preferred injectable CGRPs? Yes No	8. Drug Name: 9. Strength: 10. Quantity Per 30 Days:		
Clinical Information Initial authorization FOR ALL DIAGNOSES: I. Is the beneficiary 18 years old or older? YesNo Is the beneficiary utilizing prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications for preventative treatment of migraines, or medication therapy for episodic cluster headaches)? YesNo Initial authorization for REVENTATUE treatment of Migraines - INJECTABLES and ORALS: Does the beneficiary have a diagnosis of migraine with or without aura based on the International Classification of Headache Disorders criteria? YesNo Does the beneficiary pave adiagnosis of migraine with or without aura based on the International Classification of Headache Disorders criteria? YesNo 3. Has the beneficiary pave medication overuse headache (MOH)? YesNo 1. For beneficiary experienced 4 or more migraine days per month for at teast 3 months? YesNo 1. For beneficiary tried and failed at least a month or greater trial of medications from at teast 2 different classes from the following list of oral medications: 1. Antidepressants (e.g., waltriptyline, venlafaxine). 2. Beta Blockers (e.g. propranolol, metoprolol, timolol, atenolol), 3. Anti- epileptics (e.g., valproate, topiramate) 4. Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (e.g., lisinopril, candesartan) 5. Calcium Channel Blockers (e.g., verapamil, nimodipine)Yes No 2. Boas the beneficiary tried and failed at least 2 preferred injectable CGRPS? Yes No 2. Convertee ONLY 2. Noll the Beneficiary tried and failed at least 2 preferred injectable CGRPS? Yes No 2. Does the Beneficiary tave end stage renal disease with a creatinine clearance (CrCI) less than 15ml/min? Yes No 2. Does the Beneficiary tave ad diagnosis of Episodic Cluster Headacher Yes No 2. Hos the beneficiary tried and failed at least 2 preferred injectable CGRPs? Yes No	11. Length of Therapy:up to 30 days60 days90 days120 days180 days365 days		
 Is the beneficiary 18 years old or older? YesNo			
 Is the beneficiary 18 years old or older? YesNo	Initial authorization FOR ALL DIAGNOSES:		
2. Is the beneficiary utilizing prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications for preventative treatment of migraines, or medication therapy for episodic cluster headaches)? YesNO			
preventative treatment of migraines, or medication therapy for episodic cluster headaches)? YesNo Initial authorization for PREVENTATIVE treatment of Migraines – INJECTABLES and ORALS: 1. Does the beneficiary have a diagnosis of migraine with or without aura based on the International Classification of Headache Disorders criteria? YesNO 2. Does the beneficiary have medication overuse headache (MOH)? YesNO 3. Has the beneficiary experienced 4 or more migraine days per month for at least 3 months? YesNO 1. For beneficiary treatment of Migraines (INJECTABLES) (Aimovig, Ajovy, Emgality 120mg/ml, and Vyepti): 1. For beneficiary treat and failed at least a month or greater trial of medications from at least 2 different classes from the following list of oral medications: 1. Antidepressants (e.g., amitriptyline, venlafaxine), 2. Beta Blockers (e.g., propranolol, metoprolol, timolol, atenolol), 3. Anti- epileaptics (e.g., valproate, topiramate) 4. Anglotensin-converting enzyme inhibitors/anglotensin II receptor blockers (e.g., lisinopril, candesartan) 5. Calcium Channel Blockers (e.g. verapamil, nimodipine)Yes No Piease list medications tried: Initial authorization for PREVENTATIVE treatment of Migraines (ORALS) (Nurte ODT, Oulipta): 1. Has the beneficiary tried and failed at least 2 preferred injectable CGRPs? Yes No 2b. Does the Beneficiary have end-stage renal disease with a creatinine clearance (CrCI) less than 15ml/min? Yes No 2. Hat the beneficiary have a diagnosis of Episodic Cluster Headache? Yes No 3. For Nertee ONLY 2a. Will the Beneficiary have a diagnosis of Episodic Cluster Headache? Yes No 2b. Does the beneficiary aver a diagnosis of Episodic Cluster Headache? Yes No 3. For beneficiary experienced 2 cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of at least 3 months? Yes No 3. For beneficiary experienced a significant decrease in the number, frequency, and/or		-	
Initial authorization for PREVENTATIVE treatment of Migraines – INJECTABLES and ORALS: 1. Does the beneficiary have a diagnosis of migraine with or without aura based on the International Classification of Headache Disorders criteria? 'VesNO			
 Does the beneficiary have a diagnosis of migraine with or without aura based on the International Classification of Headache Disorders criteria? YesNo Does the beneficiary have medication overuse headache (MOH)? YesNo Has the beneficiary experienced 4 or more migraine days per month for at least 3 months? YesNo Initial authorization for PREVENTATIVE treatment of Migraines (INJECTABLES) (Ainovig, Ajovy, Engality 120mg/ml, and Vyepti): For beneficiary tried and failed at least a month or greater trial of medications from at least 2 different classes from the following list of oral medications: Antidepressants (e.g., amitriptyline, venlafaxine), 2. Beta Blockers (e.g. propranolol, metoprolol, timolol, atenolol), 3. Anti-epileptics (e.g., valproate, topiramate) 4. Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (e.g., lisinopril, candesartan) Calcium Channel Blockers (e.g. verapamil, nimodipine)YesNo Please list medications fried:			
criteria? YesNo 2. Does the beneficiary experienced 4 or more migraine days per month for at least 3 months? YesNo Initial authorization for PREVENTATIVE treatment of Migraines (INJECTABLES) (Aimovig, Ajovy, Emgality 120mg/ml, and Vyepti): 1. For beneficiary experienced 4 or more migraine days per month for at least 3 months? YesNo 2. Has the beneficiary tried and failed at least a month or greater trial of medications from at least 2 different classes from the following list of oral medications: 1. Antidepressants (e.g., amitriptyline, venlafaxine), 2. Beta Blockers (e.g., propranolol, metoprolol, timolol, atenolol), 3. Anti-epileptics (e.g., valproate, topiramate) 4. Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (e.g., lisinopril, candesartan) 5. Calcium Channel Blockers (e.g., verapamil, nimodipine)Yes No		lers	
 3. Has the beneficiary experienced 4 or more migraine days per month for at least 3 months? YesNo			
 3. Has the beneficiary experienced 4 or more migraine days per month for at least 3 months? YesNo	2. Does the beneficiary have medication overuse headache (MOH)? YesNo		
Initial authorization for PREVENTATIVE treatment of Migraines (INJECTABLES) (Aimovig, Ajovy, Emgality 120mg/ml, and Vyepti): 1. For beneficiaries that are women of childbearing age, is there a negative pregnancy test at baseline? YesNo 2. Has the beneficiary tried and failed at least a month or greater trial of medications from at least 2 different classes from the following list of oral medications: 1. Antidepressants (e.g., amitriptyline, venlafaxine), 2. Beta Blockers (e.g. propranolol, metoprolol, timolol, atenolol), 3. Anti-epileptics (e.g., valproate, topiramate) 4. Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (e.g., lisinopril, candesartan) 5. Calcium Channel Blockers (e.g. verapamil, nimodipine)Yes No Please list medications tried:			
1. For beneficiaries that are women of childbearing age, is there a negative pregnancy test at baseline? YesNo 2. Has the beneficiary tried and failed at least a month or greater trial of medications from at least 2 different classes from the following list of oral medications: 1. Antidepressants (e.g., amitriptyline, venlafaxine), 2. Beta Blockers (e.g. propranolol, metoprolol, timolol, atenolol), 3. Anti- epileptics (e.g., valproate, topiramate) 4. Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (e.g., lisinopril, candesartan) 5. Calcium Channel Blockers (e.g. verapamil, nimodipine)YesNo Please list medications tried:			
 2. Has the beneficiary tried and failed at least a month or greater trial of medications from at least 2 different classes from the following list of oral medications: 1. Antidepressants (e.g., amitriptyline, venlafaxine), 2. Beta Blockers (e.g. propranolol, metoprolol, timolol, atenolol), 3. Anti-epileptics (e.g., valproate, topiramate) 4. Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (e.g., lisinopril, candesartan) 5. Calcium Channel Blockers (e.g., verapamil, nimodipine)Yes No Please list medications tried:			
oral medications: 1. Antidepressants (e.g., amitriptyline, venlafaxine), 2. Beta Blockers (e.g. propranolol, metoprolol, timolol, atenolol), 3. Anti- epileptics (e.g., valproate, topiramate) 4. Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (e.g., lisinopril, candesartan) 5. Calcium Channel Blockers (e.g. verapamil, nimodipine)YesNo		ng list of	
epileptics (e.g., valproate, topiramate) 4. Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (e.g., lisinopril, candesartan) 5. Calcium Channel Blockers (e.g., verapamil, nimodipine)YesNo Please list medications tried: Initial authorization for PREVENTATIVE treatment of Migraines (ORALS) (Nurtec ODT, Qulipta): 1. Has the beneficiary tried and failed at least 2 preferred injectable CGRPs? YesNo 2. For Nurtec ONLY 2a. Will the Beneficiary use Nurtec concurrently with a strong CYP3A4 inhibitor? YesNo 2b. Does the Beneficiary have end-stage renal disease with a creatinine clearance (CrCl) less than 15ml/min? YesNo 2b. Does the Beneficiary have and diagnosis of Episodic Cluster Headache? YesNo 2. Has the beneficiary experienced 2 cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of at least 3 months? YesNo 3. For beneficiary experienced a significant decrease in the number, frequency, and/or intensity of headaches and/or decrease in the length of the cluster period? YesNo 2. Has the beneficiary experienced a significant decrease in the number, frequency, and/or intensity of headaches and/or decrease in the length of the cluster period? YesNo 2. Has the beneficiary experienced an overall improvement in function with therapy? YesNo 3. Does the beneficiary experienced an overall improvement in function modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications, medications)? YesNo 4. If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? YesNo (not required for Nurtec or Qulipta)		•	
 5. Calcium Channel Blockers (e.g. verapamil, nimodipine)YesNo Please list medications tried:		-	
Please list medications tried:		indeced (dr.)	
Initial authorization for PREVENTATIVE treatment of Migraines (ORALS) (Nurtec ODT, Oulipta): 1. Has the beneficiary tried and failed at least 2 preferred injectable CGRPs? Yes No 2. For Nurtec ONLY 2a. Will the Beneficiary use Nurtec concurrently with a strong CYP3A4 inhibitor? Yes No 2b. Does the Beneficiary have end-stage renal disease with a creatinine clearance (CrCl) less than 15ml/min? Yes No Initial authorization for treatment of Episodic Cluster Headache in Adults (Emgality 100mg/ml): 1. Does the beneficiary experienced 2 cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of at least 3 months? Yes No 3. For beneficiaries that are women of childbearing age, is there a negative pregnancy test at baseline? Yes No 1. Has the beneficiary experienced a significant decrease in the number, frequency, and/or intensity of headaches and/or decrease in the length of the cluster period? Yes No 2. Has the beneficiary experienced a noverall improvement in function with therapy? Yes No 3. Does the beneficiary continue to utilize prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications, medications)? Yes No 4. If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? Yes No 4. If the beneficiary experienced and childbearing age, is the provider continuing to monitor for pregnancy status? Yes No			
 Has the beneficiary tried and failed at least 2 preferred injectable CGRPs? YesNo For Nurtec ONLY 2a. Will the Beneficiary use Nurtec concurrently with a strong CYP3A4 inhibitor? YesNo 2b. Does the Beneficiary have end-stage renal disease with a creatinine clearance (CrCl) less than 15ml/min? YesNo Initial authorization for treatment of Episodic Cluster Headache in Adults (Emgality 100mg/ml): Does the beneficiary have a diagnosis of Episodic Cluster Headache? Yes No Has the beneficiary experienced 2 cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of at least 3 months? Yes No For beneficiaries that are women of childbearing age, is there a negative pregnancy test at baseline? Yes No For re-authorization for all diagnoses: Has the beneficiary experienced a significant decrease in the number, frequency, and/or intensity of headaches and/or decrease in the length of the cluster period? Yes No Has the beneficiary experienced an overall improvement in function with therapy? Yes No Boes the beneficiary continue to utilize prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications, medications)? Yes No			
 2. For Nurtec ONLY 2a. Will the Beneficiary use Nurtec concurrently with a strong CYP3A4 inhibitor? Yes No 2b. Does the Beneficiary have end-stage renal disease with a creatinine clearance (CrCl) less than 15ml/min? Yes No Initial authorization for treatment of Episodic Cluster Headache in Adults (Emgality 100mg/ml): 1. Does the beneficiary have a diagnosis of Episodic Cluster Headache? Yes No 2. Has the beneficiary experienced 2 cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of at least 3 months? Yes No 3. For beneficiaries that are women of childbearing age, is there a negative pregnancy test at baseline? Yes No Thas the beneficiary experienced a significant decrease in the number, frequency, and/or intensity of headaches and/or decrease in the length of the cluster period? Yes No 2. Has the beneficiary experienced an overall improvement in function with therapy? Yes No 3. Does the beneficiary continue to utilize prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications, medications)? Yes No 4. If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? Yes No 			
 2a. Will the Beneficiary use Nurtec concurrently with a strong CYP3A4 inhibitor? YesNo 2b. Does the Beneficiary have end-stage renal disease with a creatinine clearance (CrCl) less than 15ml/min? YesNo Initial authorization for treatment of Episodic Cluster Headache in Adults (Emgality 100mg/ml): 1. Does the beneficiary have a diagnosis of Episodic Cluster Headache? YesNo 2. Has the beneficiary experienced 2 cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of at least 3 months? YesNo 3. For beneficiaries that are women of childbearing age, is there a negative pregnancy test at baseline? YesNo Thas the beneficiary experienced a significant decrease in the number, frequency, and/or intensity of headaches and/or decrease in the length of the cluster period? YesNo 2. Has the beneficiary experienced an overall improvement in function with therapy? YesNo 3. Does the beneficiary continue to utilize prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications, medications)? YesNo 4. If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? YesNo 			
 2b. Does the Beneficiary have end-stage renal disease with a creatinine clearance (CrCl) less than 15ml/min? YesNo Initial authorization for treatment of Episodic Cluster Headache in Adults (Emgality 100mg/ml): Does the beneficiary have a diagnosis of Episodic Cluster Headache? YesNo Has the beneficiary experienced 2 cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of at least 3 months? YesNo For beneficiaries that are women of childbearing age, is there a negative pregnancy test at baseline? YesNo Has the beneficiary experienced a significant decrease in the number, frequency, and/or intensity of headaches and/or decrease in the length of the cluster period? YesNo Has the beneficiary experienced an overall improvement in function with therapy? YesNo Does the beneficiary continue to utilize prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications, medications)? YesNo If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? YesNo 			
Initial authorization for treatment of Episodic Cluster Headache in Adults (Emgality 100mg/ml): 1. Does the beneficiary have a diagnosis of Episodic Cluster Headache? YesNo 2. Has the beneficiary experienced 2 cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of at least 3 months? YesNo 3. For beneficiaries that are women of childbearing age, is there a negative pregnancy test at baseline? YesNo For re-authorization for all diagnoses: 1. Has the beneficiary experienced a significant decrease in the number, frequency, and/or intensity of headaches and/or decrease in the length of the cluster period? YesNo 2. Has the beneficiary experienced an overall improvement in function with therapy? YesNo 3. Does the beneficiary continue to utilize prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications, medications)? YesNo 4. If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? YesNo (not required for Nurtec or Qulipta)			
 Does the beneficiary have a diagnosis of Episodic Cluster Headache? YesNo Has the beneficiary experienced 2 cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of at least 3 months? YesNo For beneficiaries that are women of childbearing age, is there a negative pregnancy test at baseline? YesNo For re-authorization for all diagnoses: Has the beneficiary experienced a significant decrease in the number, frequency, and/or intensity of headaches and/or decrease in the length of the cluster period? YesNo Has the beneficiary experienced an overall improvement in function with therapy? YesNo Does the beneficiary continue to utilize prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications, medications)? YesNo If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? YesNo 			
 2. Has the beneficiary experienced 2 cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of at least 3 months? YesNo 3. For beneficiaries that are women of childbearing age, is there a negative pregnancy test at baseline? YesNo For re-authorization for all diagnoses: Has the beneficiary experienced a significant decrease in the number, frequency, and/or intensity of headaches and/or decrease in the length of the cluster period? Yes No Has the beneficiary experienced an overall improvement in function with therapy? Yes No Boes the beneficiary continue to utilize prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications, medications)? Yes No If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? Yes No 			
of at least 3 months? YesNo 3. For beneficiaries that are women of childbearing age, is there a negative pregnancy test at baseline? YesNo For re-authorization for all diagnoses: 1. Has the beneficiary experienced a significant decrease in the number, frequency, and/or intensity of headaches and/or decrease in the length of the cluster period? YesNo 2. Has the beneficiary experienced an overall improvement in function with therapy? YesNo 3. Does the beneficiary continue to utilize prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications, medications)? YesNo 4. If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? YesNo (not required for Nurtec or Oulipta)		ion periods	
 3. For beneficiaries that are women of childbearing age, is there a negative pregnancy test at baseline? YesNo For re-authorization for all diagnoses: Has the beneficiary experienced a significant decrease in the number, frequency, and/or intensity of headaches and/or decrease in the length of the cluster period? Yes No Has the beneficiary experienced an overall improvement in function with therapy? Yes No Does the beneficiary continue to utilize prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications, medications)? Yes No If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? Yes No (not required for Nurtec or Oulipta) 		ion ponodo	
For re-authorization for all diagnoses: 1. Has the beneficiary experienced a significant decrease in the number, frequency, and/or intensity of headaches and/or decrease in the length of the cluster period? Yes No 2. Has the beneficiary experienced an overall improvement in function with therapy? Yes No 3. Does the beneficiary continue to utilize prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications, medications)? Yes No 4. If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? Yes No (not required for Nurtec or Oulipta)			
 Has the beneficiary experienced a significant decrease in the number, frequency, and/or intensity of headaches and/or decrease in the length of the cluster period? YesNo Has the beneficiary experienced an overall improvement in function with therapy? YesNo Does the beneficiary continue to utilize prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications), medications)? YesNo If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? YesNo If the previder or Qulipta) 			
of the cluster period? YesNo 2. Has the beneficiary experienced an overall improvement in function with therapy? YesNo 3. Does the beneficiary continue to utilize prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications, medications)? YesNo 4. If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? YesNo (not required for Nurtec or Oulipta)		the length	
 2. Has the beneficiary experienced an overall improvement in function with therapy? Yes No 3. Does the beneficiary continue to utilize prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications, medications)? Yes No 4. If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? Yes No (not required for Nurtec or Qulipta) 			
 Does the beneficiary continue to utilize prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, lifestyle modifications, medications)? Yes No If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? Yes No (not required for Nurtec or Qulipta) 			
modifications, medications)? YesNo 4. If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? YesNo (not required for Nurtec or Qulipta)	5 1 1 15		
4. If the beneficiary is a woman of childbearing age, is the provider continuing to monitor for pregnancy status? YesNo (not required for Nurtec or Qulipta)			
(not required for Nurtec or Qulipta)			
5 Is the heneficiary experiencing unaccentable toxicity (e.g., intolerable injection site pain, constinution)? Vos	(not required for Nurtec or Qulipta)		
	5. Is the beneficiary experiencing unacceptable toxicity (e.g., intolerable injection site pain, constipation)? Yes No		

Signature of Prescriber: _____

Date: _____

*Prescriber signature mandatory

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.